UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.102

Sortiert nach

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

Annals of oncology, 2015-06, Vol.26 (6), p.1188-1194

2015

Link zum Volltext

Verfügbarkeit prüfen

FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials

Annals of oncology, 2016-05, Vol.27 (5), p.843-849

2016

Link zum Volltext

Verfügbarkeit prüfen

Access of the oncologic patients to the emergency room of the local hospital during the three-year period 2014–2016

Annals of oncology, 2017-10, Vol.28, p.vi99-vi99

2017

Link zum Volltext

Verfügbarkeit prüfen

Drug Delivery in Dermatology: Fundamental and Practical Applications

1st ed. 2021., 2021

Link zum Volltext

Verfügbarkeit prüfen

Treatment in advanced malignant pleural mesothelioma after chemotherapy standard

Annals of oncology, 2016-09, Vol.27, p.iv15

2016

Link zum Volltext

Verfügbarkeit prüfen

Malignant pleural mesothelioma: Scheme therapeutic after standard treatment (study of phase II)

European journal of cancer supplements, 2008-10, Vol.6 (14), p.150-150

2008

Link zum Volltext

Verfügbarkeit prüfen

Treatment in metastatic prostate cancer with hormone refractory

European journal of cancer supplements, 2008-10, Vol.6 (14), p.1-1

2008

Link zum Volltext

Verfügbarkeit prüfen

Integrated regimen therapeutic (polybiologic-chemotherapy) for melanoma advanced

European journal of cancer supplements, 2008-10, Vol.6 (14), p.135-135

2008

Link zum Volltext

Verfügbarkeit prüfen

A metronomic treatment with oral chemotherapy in patients elderly with metastatic breast cancer

European journal of cancer supplements, 2008-10, Vol.6 (14), p.116-117

2008

Link zum Volltext

Verfügbarkeit prüfen

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

The lancet oncology, 2020-04, Vol.21 (4), p.497-507

2020

Link zum Volltext

Verfügbarkeit prüfen

Comparative Effectiveness and Safety of Bariatric Procedures for Weight Loss: A PCORnet Cohort Study

Annals of internal medicine, 2018-12, Vol.169 (11), p.741

2018

Link zum Volltext

Verfügbarkeit prüfen

Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): a multicentre phase II clinical trial

Lung cancer (Amsterdam, Netherlands), 2001-10, Vol.34 (1), p.115-123

2001

Link zum Volltext

Verfügbarkeit prüfen

Cognitive and neural mechanisms underlying semantic ambiguity resolution

Vitello, S

2014

Link zum Volltext
ProQuest

Folfoxiri with or Without Bevacizumab (Bev) As First-Line Treatment of Metastatic Colorectal Cancer (Mcrc): a Propensity Score-Based Analysis

Annals of oncology, 2014-09, Vol.25, p.iv175

2014

Link zum Volltext

Verfügbarkeit prüfen

DPYD c.1905 + 1G > A and c.2846A > T and UGT1A128 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer

Annals of oncology, 2015-10, Vol.26, p.vi38

2015

Link zum Volltext

Verfügbarkeit prüfen

Subgroup Analyses in RAS Mutant, BRAF Mutant and “ALL WT” Metastatic Colorectal Cancer Patients Treated with Folfoxiri Plus Bevacizumab (BEV) or Folfiri Plus BEV in the Tribe Study

Annals of oncology, 2014-06, Vol.25, p.ii107-ii107

2014

Link zum Volltext

Verfügbarkeit prüfen

Inclusive schooling: National and international perspectives

1998

Link zum Volltext

Verfügbarkeit prüfen

Memory B cell subpopulations in the aged

Rejuvenation research, 2006-03, Vol.9 (1), p.149

2006

Link zum Volltext

Verfügbarkeit prüfen

Reductions in alanine aminotransferase levels with liraglutide treatment are greatest in those with raised baseline levels and are independent of weight loss: real-world outcome data from the ABCD Nationwide Liraglutide Audit

British Journal of Diabetes, 2019-12, Vol.19 (2), p.118-123

2019

Link zum Volltext

Verfügbarkeit prüfen

Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone

Neurology, 2011-11, Vol.77 (21), p.1887

2011

Link zum Volltext

Verfügbarkeit prüfen

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

Annals of oncology, 2015-06, Vol.26 (6), p.1188

2015

Link zum Volltext

Verfügbarkeit prüfen

The National Patient-Centered Clinical Research Network (PCORnet) Bariatric Study Cohort: Rationale, Methods, and Baseline Characteristics

JMIR research protocols, 2017-12, Vol.6 (12), p.e222-e222

2017

Link zum Volltext

Verfügbarkeit prüfen

The triplet combination of irinotecan, oxaliplatin and 5FU/LV (FOLFOXIRI) vs the doublet of irinotecan and 5FU/LV (FOLFIRI) as first-line treatment of metastatic colorectal cancer (MCRC): Results of a randomized phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.)

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.3513-3513

2006

Link zum Volltext

Verfügbarkeit prüfen

Special Education Integration: The Arezzo Approach

International journal of disability, development, and education, 1994-01, Vol.41 (1), p.61-70

Vitello, Stanley J.

1994

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.102

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(527)
Mit Volltextzugriff
(621)

Publikationsform

6 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Daily Herald
(255)
Juxtapoz
(73)
Biochemistry
(25)
Propellants, Explosives, Pyrotechnics
(25)
Digestive And Liver Disease
(13)
The Astrophysical Journal
(12)
Comparative Connections
(11)
Annals Of Oncology
(10)
Ieee Transactions On Plasma Science
(10)
Surgical & Cosmetic Dermatology
(10)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials

Access of the oncologic patients to the emergency room of the local hospital during the three-year period 2014–2016

Drug Delivery in Dermatology: Fundamental and Practical Applications

Treatment in advanced malignant pleural mesothelioma after chemotherapy standard

Malignant pleural mesothelioma: Scheme therapeutic after standard treatment (study of phase II)

Treatment in metastatic prostate cancer with hormone refractory

Integrated regimen therapeutic (polybiologic-chemotherapy) for melanoma advanced

A metronomic treatment with oral chemotherapy in patients elderly with metastatic breast cancer

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Comparative Effectiveness and Safety of Bariatric Procedures for Weight Loss: A PCORnet Cohort Study

Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): a multicentre phase II clinical trial

Cognitive and neural mechanisms underlying semantic ambiguity resolution

Folfoxiri with or Without Bevacizumab (Bev) As First-Line Treatment of Metastatic Colorectal Cancer (Mcrc): a Propensity Score-Based Analysis

DPYD c.1905 + 1G > A and c.2846A > T and UGT1A128 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer

Outcomes After Endovascular Therapy With Procedural Sedation vs General Anesthesia in Patients With Acute Ischemic Stroke: The AMETIS Randomized Clinical Trial

Subgroup Analyses in RAS Mutant, BRAF Mutant and “ALL WT” Metastatic Colorectal Cancer Patients Treated with Folfoxiri Plus Bevacizumab (BEV) or Folfiri Plus BEV in the Tribe Study

Inclusive schooling: National and international perspectives

Memory B cell subpopulations in the aged

Reductions in alanine aminotransferase levels with liraglutide treatment are greatest in those with raised baseline levels and are independent of weight loss: real-world outcome data from the ABCD Nationwide Liraglutide Audit

Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

The National Patient-Centered Clinical Research Network (PCORnet) Bariatric Study Cohort: Rationale, Methods, and Baseline Characteristics

The triplet combination of irinotecan, oxaliplatin and 5FU/LV (FOLFOXIRI) vs the doublet of irinotecan and 5FU/LV (FOLFIRI) as first-line treatment of metastatic colorectal cancer (MCRC): Results of a randomized phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.)

Special Education Integration: The Arezzo Approach

Suchergebnisse filtern